Rajnish Wellness (541601)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 156.51% shows strong topline momentum and market traction.
• Latest quarter revenue of ₹23 crore suggests the business is generating meaningful scale.
• Positive book value of ₹0.87 per share provides a small tangible asset cushion.
• Marginal positive ROCE of 0.59% indicates some ability to earn a return on capital employed.

Concerns

• P/E of 0.00 and profit growth of -1400%: there are no real earnings to justify the price.
• Negative ROE of -1.29% while paying 4.99 times book value means shareholders are paying a premium for value destruction.
• Piotroski F-Score of 4/9 signals weak financial health and operating fundamentals.
• No dividend and no promoter holding disclosure reduce reassurance for minority investors.

AI Analysis

At ₹4.34, with a market cap of ₹334 crore, Rajnish Wellness offers a story, not a statement. The topline jumped 156.51%, and the latest quarter shows ₹23 crore in sales. But my eyes go to the bottom line: net profit of minus ₹1 crore, profit growth of minus 1400%, and a P/E of zero because there are no real earnings to capitalize. Graham's first rule is that an investor should purchase on the basis of value, not enthusiasm. Here I am asked to pay 4.99 times book value for a business earning a negative 1.29% ROE and a negligible 0.59% ROCE. That is no margin of safety. The Piotroski F-score of 4/9 reinforces the picture: weak profitability, questionable efficiency, and poor financial health. There is no dividend to hold my hand while I wait. I cannot even see promoter holding in the data, so I cannot judge whether insiders have skin in the game. The 52-week range, from ₹0.39 to ₹4.34, tells me the market has already priced in a miracle. A ten-bagger rally does not make an investment; it makes the risk greater. In the pharmaceutical and wellness space, without a proprietary moat or a proven earnings stream, this is not a compounding machine. It is a speculative turnaround candidate. I would need several quarters of positive net profit, clearer debt position, improving returns, and clearer governance before I would consider buying. Until then, the sensible action is to sit on my hands. Price is what you pay; value is what you get. Here, I don't see enough value to justify this price.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer